Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970. The authors have advised that there are errors in the first row of Table 5 on page 963. Cariprazine 4.5 mg column, the value “1 (0.0)” should ...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:doaj.org-article:cf336b8f9cd74908af6e74a46e31c7e7 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:cf336b8f9cd74908af6e74a46e31c7e72021-12-02T14:36:43ZSafety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]1178-2021https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e72021-05-01T00:00:00Zhttps://www.dovepress.com/corrigendum-safety-and-tolerability-of-cariprazine-in-patients-with-sc-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970. The authors have advised that there are errors in the first row of Table 5 on page 963. Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”. The authors apologize for these errors. Read the original articleBarabássy ÁSebe BAcsai KLaszlovszky ISzatmári BEarley WRNémeth GDove Medical Pressarticlecariprazineatypical antipsychoticschizophreniasafety and tolerabilitypost hoc analysisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1481-1482 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
cariprazine atypical antipsychotic schizophrenia safety and tolerability post hoc analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
spellingShingle |
cariprazine atypical antipsychotic schizophrenia safety and tolerability post hoc analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Barabássy Á Sebe B Acsai K Laszlovszky I Szatmári B Earley WR Németh G Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
description |
Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970.
The authors have advised that there are errors in the first row of Table 5 on page 963.
Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”.
The authors apologize for these errors.
Read the original article |
format |
article |
author |
Barabássy Á Sebe B Acsai K Laszlovszky I Szatmári B Earley WR Németh G |
author_facet |
Barabássy Á Sebe B Acsai K Laszlovszky I Szatmári B Earley WR Németh G |
author_sort |
Barabássy Á |
title |
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
title_short |
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
title_full |
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
title_fullStr |
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
title_full_unstemmed |
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum] |
title_sort |
safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase ii/iii studies [corrigendum] |
publisher |
Dove Medical Press |
publishDate |
2021 |
url |
https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e7 |
work_keys_str_mv |
AT barabassya safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT sebeb safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT acsaik safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT laszlovszkyi safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT szatmarib safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT earleywr safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum AT nemethg safetyandtolerabilityofcariprazineinpatientswithschizophreniaapooledanalysisofeightphaseiiiiistudiescorrigendum |
_version_ |
1718391036878782464 |